
United Therapeutics completes first UThymoKidney transplant
Key points
- United Therapeutics (NASDAQ:UTHR) announced the first clinical transplant of its investigational UThymoKidney in a patient with end-stage renal disease.
- The procedure was performed at NYU Langone Health as part of the EXTEND clinical trial evaluating the safety and effectiveness of a genetically modified pig kidney.
- The study aims to assess whether incorporating porcine thymic tissue can help the human immune system accept a transplanted pig kidney and reduce organ rejection.
United Therapeutics Corporation (NASDAQ:UTHR) announced the first transplant in its EXTEND clinical trial, evaluating its investigational UThymoKidney in a patient with end-stage renal disease (ESRD) at NYU Langone Health.
The study will evaluate the safety and effectiveness of the porcine thymokidney in patients who are ineligible for conventional kidney transplantation or face a higher likelihood of dying or remaining without a transplant within five years.
"Today marks an exciting moment for United Therapeutics and for the field of xenotransplantation," said Jayme Locke, chief medical officer of xenotransplantation at United Therapeutics.
The UThymoKidney comes from a genetically modified pig whose alpha-gal-producing gene has been disabled, while its thymic tissue is intended to help the recipient's immune system recognize the transplanted organ and reduce rejection risk.
Following the announcement, United Therapeutics' share price was down 2.33% at US$562.38 on November 20, 2026.
EXTEND is the second clinical trial in United Therapeutics' xeno-organ manufacturing programme, following EXPAND, which evaluates its investigational UKidney in patients with end-stage renal disease.
The company is also developing UHeart through its EXPRESS clinical trial for patients with advanced heart failure and operates three designated pathogen-free facilities to support the production of investigational transplantable organs.


-640x360.webp&w=3840&q=75)
